Eramet Shares Plunge 10% in a Week Following Analyst Downgrade

Analyst Downgrade and Revised Price Target

On Thursday, March 12, the analysis firm Alphavalue changed its opinion on Eramet, shifting from a 'buy' to 'accumulate' recommendation. At the same time, the price target was reduced from €76.60 to €65.60, still representing a potential revaluation of about 26% compared to the current price of €52.15. This change accompanies a difficult period for the stock: Eramet has lost more than 10% in seven days and shows a decline of nearly 11% over the year. The next key date that might provide new insights to the markets is set for April 23, when the group will publish its first quarter 2026 revenue. Meanwhile, the CAC 40 is stable during the session, around 7,984 points, while the SBF 120 is down 0.01%. Eramet's underperformance is thus clearly decoupled from the general trend of the Paris market this Friday.

Technical Analysis and Market Position

From a technical standpoint, Eramet's share price is now trading well below its 50-day moving average, set at €66.16, and has just fallen below its 200-day moving average (€55.71). This double downward crossover indicates a deterioration in the medium-term dynamics: the stock, which was still trading above these two benchmarks at the beginning of February, has rapidly moved away from them in recent sessions. The nearest technical support is located at €46.10, approximately 12% below current levels, while major resistance is at €76.20. Monthly volatility remains high, at 34.75, reflecting the extent of recent fluctuations. The RSI indicator, at 57, does not yet signal an oversold condition, suggesting the possibility of a continued downward movement before any potential technical rebound occurs.